Multiple Myeloma

EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy

Allogene's Preclinical Data Show Healthy Donor-Derived Allogeneic CAR T Cells Have Better Immune Fitness, Killing Activity

Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum

Allogene's Preclinical Data Show Healthy Donor-Derived Allogeneic CAR T Cells Have Better Immune Fitness, Killing Activity

Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum

Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients

Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet

Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients

Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet

JNJ's Janssen Posts Two Years Survival Data On BCMA Cell Therapy In Multiple Myeloma

AbbVie, SpringWorks Join Forces To Conduct Multiple Myeloma Combo Therapy Trial

Multiple Myeloma Recent News

iTeos Posts New Preclinical Data For Anti-TIGIT Antibody At ASH 2021

ITeos Therapeutics Inc (NASDAQ: ITOS)

Why Are Legend Biotech Shares Gaining Today?

Janssen's Subcutaneous Darzalex Combo Wins FDA Approval For Pretreated Multiple Myeloma

Johnson & Johnson's (NYSE: JNJ) Janssen Biotech Inc has

Gracell Biotech Stock Jumps On Orphan Drug Tag For Multiple Myeloma CAR-T Cell Therapy

Poseida's Fully Allogeneic CAR-T Product Enters Human Trial For Multiple Myeloma

UK's NICE Rejects Johnson & Johnson's Darzalex Regime For Newly Diagnosed Myeloma

New guidance from the National Institute for Health and Care Excellence (NICE) has rejected a combination regimen based on Johnson & Johnson's (NYSE: JNJ) Darzalex for previously untreated patients with multiple myeloma.

Europe Approves Bristol Myers' BCMA-Targeted Multiple Myeloma Immunotherapy

Allogene's BCMA-Targeted Therapy Gets US Orphan Drug Tag For Multiple Myeloma

C4 Therapeutics Multiple Myeloma Candidate Scores FDA Orphan Drug Tag

Sorrento Therapeutics To Start Testing DAR-T Cell Therapy In Multiple Myeloma Patients

Janssen's Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma

Sanofi Bets Over $1B For Eureka's Multiple Myeloma Candidate

Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial

Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models

Johnson & Johnson Building Case With New Patient Survival Data For Darzalex In Multiple Myeloma

Legend Biotech-Janssen's Multiple Myeloma Cell Therapy Under Review In US

Celyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy

BioLineRx Stock Is Trading Higher As Motixafortide-G-CSF Combo Shows Promise In Transplant Setting For Multiple Myeloma Patients

SpringWorks Therapeutics Stock Is Trading Higher After Nirogacestat Combo Study Starts Dosing In Multiple Myeloma Patients

SpringWorks Therapeutics Inc (NASDAQ: SWTX) has dosed the first patient in a Phase 1b clinical trial evaluating nirogacestat combined with Janssen's teclistamab in patients with relapsed or refractory multiple myeloma. Nirogacestat is an investigational gamma-secretase inhibitor (GSI) developed by SpringWorks.

Karyopharm's Partner Antengene Receives Priority Review For Selinexor Application In China

GlaxoSmithKline Gets FDA Approval For Blood Cancer Drug

GlaxoSmithKline plc (NYSE: GSK) announced Wednesday the United States Food and Drug Administration had approved its cancer drug aimed at treating refractory multiple myeloma in adults.

Karyopharm Shares Nosedive On Tough FDA Briefing For Multiple Myeloma Drug

;